Fig. 1: WGS Pathway. | BJC Reports

Fig. 1: WGS Pathway.

From: Introduction of whole genome sequencing as NHS standard of care for glioma patients in two neurosurgical oncology centres: West Midlands

Fig. 1

Patient are identified at the weekly neuro-oncology multi-disciplinary team meeting (MDT), WGS forms are completed at the weekly neurosurgical clinic. Tissue sampling of paired fresh frozen tumour and blood samples must be co-ordinated with the associated forms at time of surgery, and transported to the pathology laboratory for standard of care serial investigations to achieve neuro-pathology diagnosis. If SOC diagnosis is not achieved tumour samples are sent to Queen Square Laboratories London for methylation array. The diagnostic code and the median tumour content is calculated and WGS request form updated. The tissue and updated forms are transported to the Regional Genomics Laboratory Hub (GLH) for DNA extraction and plating, and then onto Illumina (Cambridge) for sequencing. WGS analysis and variant calling is completed by Genomics England. The data is sent to the GLH for disease-specific analysis, and discussed in the fortnightly Genomics Tumour Advisory Board (GTAB) before a final report is finalised and sent to the treating oncologist. Patients with actionable variants are discussed in the neuro-oncology MDT.

Back to article page